Elizabeth Colston

848 total citations
21 papers, 638 citations indexed

About

Elizabeth Colston is a scholar working on Immunology, Oncology and Pharmacology. According to data from OpenAlex, Elizabeth Colston has authored 21 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 7 papers in Oncology and 6 papers in Pharmacology. Recurrent topics in Elizabeth Colston's work include Psoriasis: Treatment and Pathogenesis (9 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Autoimmune Bullous Skin Diseases (3 papers). Elizabeth Colston is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (9 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Autoimmune Bullous Skin Diseases (3 papers). Elizabeth Colston collaborates with scholars based in United States, Germany and Japan. Elizabeth Colston's co-authors include Vincent R. Racaniello, Dennis M. Grasela, Scott C. Brakenridge, Florian Mayr, Pauline K. Park, Derek C. Angus, Elliott D. Crouser, Craig M. Coopersmith, June Ye and Sachin Yende and has published in prestigious journals such as The EMBO Journal, PLoS ONE and Journal of Virology.

In The Last Decade

Elizabeth Colston

20 papers receiving 628 citations

Peers

Countries citing papers authored by Elizabeth Colston

Since Specialization

Citations

This map shows the geographic impact of Elizabeth Colston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Colston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Colston more than expected).

Fields of papers citing papers by Elizabeth Colston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Colston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Colston. The network helps show where Elizabeth Colston may publish in the future.

Co-authorship network of co-authors of Elizabeth Colston

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Colston. A scholar is included among the top collaborators of Elizabeth Colston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Colston. Elizabeth Colston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2) 2024 ·Journal of the European Academy of Dermatology and Venereology ·Bruce Strober, Andrew Blauvelt, Richard B. Warren, Kim Papp, April W. Armstrong, Kenneth B. Gordon, Akimichi Morita, Andrew Alexis, Mark Lebwohl, Peter Foley, Renata M. Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi	27
2	Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial 2024 ·The Journal of Dermatology ·Shinichi Imafuku, Yukari Okubo, Yayoi Tada, Mamitaro Ohtsuki, Elizabeth Colston, Andrew Napoli, (unknown), Subhashis Banerjee, Akimichi Morita	23
3	Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program 2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Richard B. Warren, Howard Sofen, (unknown), C. Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, (unknown), Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt	3
4	Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis 2023 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Phoebe Rich, Howard Sofen, Bruce Strober, Joseph F. Merola, Mark Lebwohl, Akimichi Morita, Jacek C. Szepietowski, Jo Lambert, (unknown), Elizabeth Colston, (unknown), Subhashis Banerjee, Diamant Thaçi	12
5	43872 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial 2023 ·Journal of the American Academy of Dermatology ·(unknown), Yukari Okubo, Yayoi Tada, Mamitaro Ohtsuki, (unknown), Elizabeth Colston, Renata M. Kisa, Subhashis Banerjee, Akimichi Morita	1
6	34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials 2022 ·Journal of the American Academy of Dermatology ·April W. Armstrong, Richard B. Warren, Howard Sofen, Lynda Spelman, Craig L. Leonardi, Subhashis Banerjee, Tao Wang, John Throup, Elizabeth Colston, Andrew Napoli, Alexa B. Kimball	2
7	Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials 2022 ·SKIN The Journal of Cutaneous Medicine ·Richard B. Warren, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, (unknown), Howard Sofen, Lynda Spelman, Neil J. Korman, Min Zheng, Elizabeth Colston, John Throup, (unknown), Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt	3
8	POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY 2021 ·Annals of the Rheumatic Diseases ·April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Elizabeth Colston, John Throup, S. Kundu, Subhashis Banerjee, Andrew Blauvelt	21
9	Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab 2019 ·Intensive Care Medicine ·Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende, Elliott D. Crouser, Greg S. Martin, Timothy E. Albertson, Raquel R. Bartz, Scott C. Brakenridge, Matthew J. Delano, Pauline K. Park, Michael W. Donnino, Mark Tidswell, Florian Mayr, Derek C. Angus, Craig M. Coopersmith, Lyle L. Moldawer, Ian M. Catlett, Ihab Girgis, June Ye, Dennis M. Grasela	136
10	Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)* 2019 ·Critical Care Medicine ·Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende, Derek C. Angus, Lyle L. Moldawer, Elliott D. Crouser, Greg S. Martin, Craig M. Coopersmith, Scott C. Brakenridge, Florian Mayr, Pauline K. Park, June Ye, Ian M. Catlett, Ihab Girgis, Dennis M. Grasela	167
11	An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients 2018 ·PLoS ONE ·Elizabeth Colston, Dennis M. Grasela, David Gardiner, R. Pat Bucy, Blisse Vakkalagadda, Alan J. Korman, Israel Lowy	23
12	1504: IMMUNE CHECKPOINT INHIBITORS IN SEPSIS: A PHASE 1B TRIAL OF ANTI-PD-L1 (BMS-936559) 2017 ·Critical Care Medicine ·(unknown), Elizabeth Colston, Sachin Yende, Derek C. Angus, Lyle L. Moldawer, Elliott D. Crouser, Greg S. Martin, Craig M. Coopersmith, Scott C. Brakenridge, Florian Mayr, Pauline Park, (unknown), Megan Wind‐Rotolo, Tao Duan, June Ye, Yi Luo, Ian M. Catlett, Khurram Rana, Dennis M. Grasela	4
13	Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation 2016 ·Journal of Interferon & Cytokine Research ·(unknown), (unknown), Megan Wind‐Rotolo, Dong Xu, Matthew Hruska, Narendra S. Kishnani, Elizabeth Colston, Subasree Srinivasan	1
14	The pharmacokinetics of peginterferon lambda‐1a following single dose administration to subjects with impaired renal function 2015 ·British Journal of Clinical Pharmacology ·Matthew Hruska, (unknown), Elizabeth Colston, Michael Hesney, (unknown), Heather Myler, Richard Bertz	3
15	822Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects 2014 ·Open Forum Infectious Diseases ·Τushar Garimella, (unknown), (unknown), Hamza Kandoussi, Michael Hesney, Elizabeth Colston, Timothy Eley, Marc Bifano	4
16	The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor 2014 ·Antiviral Therapy ·Timothy Eley, Bing He, Ih Chang, Elizabeth Colston, Michael Child, (unknown), Hamza Kandoussi, C Pasquinelli, Thomas Marbury, Richard Bertz	27
17	Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition 1995 ·Journal of Virology ·Elizabeth Colston, Vincent R. Racaniello	64
18	Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. 1994 ·The EMBO Journal ·Elizabeth Colston, Vincent R. Racaniello	89
19	Integration of the BALB/c ecotropic provirus into the colony-stimulating factor-1 growth factor locus in a myc retrovirus-induced murine monocyte tumor 1988 ·Journal of Virology ·W R Baumbach, Elizabeth Colston, Michael D. Cole	24
20	Color and Culture in South Africa. 1956 ·The Journal of Negro Education ·Elizabeth Colston, Sheila Patterson	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact